Amgen Inc. (AMGN) Stake Raised by AGF Investments Inc.
AGF Investments Inc. boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 59.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 260,649 shares of the medical research company’s stock after buying an additional 97,269 shares during the period. AGF Investments Inc.’s holdings in Amgen were worth $42,715,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC acquired a new stake in shares of Amgen during the first quarter worth approximately $121,000. Signature Estate & Investment Advisors LLC raised its stake in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares in the last quarter. Finally, Cribstone Capital Management LLC raised its stake in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after buying an additional 25 shares in the last quarter. 78.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of Amgen Inc. (AMGN) traded up 0.53% during midday trading on Friday, hitting $178.71. 2,432,318 shares of the stock were exchanged. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The firm has a market capitalization of $130.40 billion, a price-to-earnings ratio of 16.28 and a beta of 1.35. The stock’s 50-day moving average price is $173.78 and its 200-day moving average price is $168.57.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the company posted $2.84 EPS. On average, analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
AMGN has been the topic of a number of research reports. BMO Capital Markets reissued a “buy” rating and issued a $198.00 price objective (down previously from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Oppenheimer Holdings, Inc. set a $189.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Mizuho set a $195.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. ValuEngine raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $195.00 price objective on shares of Amgen in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $186.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.